Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum

Key facts

Sponsor

Arena Pharmaceuticals

Principal Investigator

Arena CT.gov Administrator

Arena Pharmaceuticals

Intervention

APD334(drug)

Enrollment

2 enrolled

Eligibility

18-80 years · All sexes

Timeline

2017 – 2018

Study locations (6)

• Westmead Hospital, Westmead, New South Wales, Australia
• Veracity Clinical Research, Woolloongabba, Queensland, Australia
• Eastern Clinical Research Unit, Box Hill, Victoria, Australia
• Royal Melbourne Hospital, Parkville, Victoria, Australia
• Fremantle Dermatology, Fremantle, Western Australia, Australia
• Braemar Day Hospital, Hamilton, New Zealand

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Classic pyoderma gangrenosum

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT06624670
  A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
  Boehringer Ingelheim
• RECRUITINGPHASE2NCT06563323
  Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
  Oregon Health and Science University

See all trials for Classic pyoderma gangrenosum →